Live attendance at SeaStar Medical's Nov. 11 results call requires preregistration.
SeaStar Medical (ICU) will report Q3 2026 results on Nov. 11, 2026, with a live call requiring preregistration. The company focuses on treatments for organ failure, with one FDA-approved product and ongoing clinical trials. ICU's SCD therapy has Breakthrough Device Designation for seven indications.
How this was made
The 30-second read
Why it matters
The announcement itself is low‑impact; traders will watch for the actual earnings release for actionable information.
Market read
The article provides only the timing of an upcoming earnings call, offering limited immediate trading relevance.
What to watch
Potential updates on the NEUTRALIZE‑AKI trial could be disclosed during the call, which may surprise the market.
Background
SeaStar Medical is a commercial‑stage biotech focused on acute kidney injury treatments. The company’s Q3 results are scheduled for Nov 11, 2026.
Ticker impact
SeaStar Medical announced the date and time of its Q3 results call on Nov. 11, 2026.
neutral impact as the market already anticipates the upcoming earnings release
No earnings numbers or guidance were disclosed; only the timing of the call was provided.
Market effects
None; the announcement does not affect the broader healthcare sector.
Limited to investors tracking SeaStar Medical.
Minimal; the news is company‑specific.
Counterpoint
If the market expects weak Q3 results, the call announcement could trigger a short‑cover rally ahead of the release.
Key entities
- companySeaStar Medical Holding Corporation
US‑listed biotech (Nasdaq: ICU) reporting Q3 results.
